Developer docs
API playgroundTry for free, no card

Search company profiles

Amprologix

Full company profile

uuid000fhes

Namestring
Amprologix
Legal namestring
Amprologix Limited
Websiteurl
amprologix.com
Company typeenum
Private
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPlymouth, United Kingdom
HQ citystring
Plymouth
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
novel antibiotics, antimicrobial peptides, antibiotic drug discovery, antimicrobial resistance, peptide therapeutics
Industry2 codes
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Novel antibiotics (antimicrobial drug discovery)
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing deals with pharmaceutical companies
TypeLicensing Royalties
Description

Amprologix plans to license its antibiotic candidates to pharmaceutical companies for commercialization. Licensing deals targeted for NI01 nasal decolonization (2026, $200M+ market) and bacterial pneumonia (2027, $5B+ market).

amprologix.com
2Grant and public funding
TypeLicensing Royalties
Description

Significant funding from Innovate UK Biomedical Catalyst awards (£1M for Tobraderm project) and SBRI funding (£1.2m for early R&D). These grants support pre-clinical development and late-preclinical testing.

amprologix.com
3Series A and subsequent funding rounds
TypeLicensing Royalties
Description

Company has raised £740,000 in pre-Series A funding (October 2025) with plans for additional funds for first human trials in 2026. Target £5M Series-A funding for 2025 skin infection clinical trials.

amprologix.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Amprologix develops Epidermicin NI01, a potent bactericidal peptide antibiotic and lead compound with no known resistance liabilities, targeting MRSA nasal decolonization, bacterial pneumonia, and topical skin/wound infections. The company also operates a proprietary AI-driven antimicrobial discovery platform that uses machine learning to identify and optimize novel peptide antibiotic candidates derived from the epidermicin family and deep-sea microorganisms. Its development pipeline is supported by an exclusively licensed compound family originally discovered by Prof Mat Upton at Manchester University.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • NI01 at 3% concentration matched efficacy of Bactroban (mupirocin) in reducing MRSA bacteria in wound infection model with no observed resistance development
+2 more records
Product overview1 text field

Amprologix is pioneering a family of new antibiotics to combat antimicrobial resistance. The core offering centers on Epidermicin NI01, a potent bactericidal peptide antibiotic with no known resistance liabilities. The company's portfolio includes the NI01 Family of novel therapeutics and an AI-Driven Antimicrobial Discovery Platform that accelerates drug candidate identification. The Tobraderm Project advances NI01 through late-preclinical testing for skin and wound infections. Together, these products form a pipeline targeting nasal decolonization (MRSA), bacterial pneumonia, and topical skin infections.

Product and service2 records
1Epidermicin NI01
CategoryNovel peptide antibiotics
Description

Amprologix's lead antibiotic compound, a potent bactericidal peptide antibiotic with no known resistance liabilities. It is being developed for nasal decolonization of MRSA (targeted for a 2026 licensing deal in a US$200M+ market), treatment of bacterial pneumonia (targeted for a 2027 licensing deal in a US$5B+ market), and topical use against skin and wound infections including impetigo and chronic wounds.

2NI01 Family (Epidermicin peptide family)
CategoryNovel peptide antibiotics
Description

A family of novel peptide therapeutics derived from minor modifications to the NI01 peptide sequence, offering a wide range of potent yet narrow-spectrum antibacterial activity against multiple bacterial pathogens. The family targets indications including MRSA, bacterial pneumonia, and surface skin infections, and represents an entirely new class of antibiotic drugs with no known resistance liabilities.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Amprologix was launched in 2018 in collaboration with University of Plymouth. CSO Prof Mat Upton is a professor at the university. The partnership focuses on translational research and antimicrobial discovery.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

World-leading biotechnology company partnered with Amprologix for manufacturing of antibiotic compounds.

Strategic tierCoreTypeTechnology or Integration
Description

Partnership to utilize cutting-edge machine learning algorithms to improve antibiotic properties through Amprologix's AI-driven drug discovery.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration using ex vivo human skin microdialysis model to test pseudo-allergic reactions for NI01 topical skin therapy, without using animal models.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Global CRO supporting both pre-clinical and clinical development of epidermicin NI01.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with Dr Max Ryadnov to publish data on the novel mode of action of epidermicin NI01, published in iScience.

7Saudi Biotechnology Accelerator
Strategic tierModerateTypeGTM or Marketing Partner
Description

Amprologix participated in the 2025 Accelerator Programme, attending the Final Forum in Riyadh. Part of Saudi Arabia's Vision 2030 strategy to become a regional biotechnology hub.

amprologix.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based commercial-stage biopharma that developed and markets Nuzyra (omadacycline), a novel antibiotic approved for community-acquired pneumonia and skin infections. Directly comparable to Amprologix as a developer of branded, novel-mechanism antibiotics targeting similar indications and the AMR problem.

TypeDirect peer
Description

US specialty biopharma with a portfolio of branded antibiotics (e.g., Baxdela) for serious and drug-resistant infections. Comparable as a focused commercial-stage novel antibiotics developer serving the same prescriber base (hospitals treating resistant infections) that Amprologix ultimately targets via licensing.

TypeDirect peer
Description

Clinical-stage biopharma developing oral and IV antibiotics (e.g., sulopenem) for multi-drug resistant infections including community-acquired pneumonia and complicated UTIs. Comparable as a late-clinical developer of branded antibiotics targeting priority pathogens on the WHO list that Amprologix addresses.

TypeDirect peer
Description

Switzerland-based clinical-stage AMR biotech developing small-molecule antibiotics (e.g., alpibectir/BVL-GSK098) to overcome resistance in priority pathogens. Comparable as a European AMR-focused biotech pursuing a licensing-oriented business model against similar bacterial targets.

TypeDirect peer
Description

UK-based clinical-stage company developing antibiotic resistance breakers and novel combinations to revive existing antibiotics. Comparable as a UK-headquartered AMR biotech in the same geographic ecosystem with a similar licensing/partnership-oriented commercial strategy.

TypeEmerging player
Description

US clinical-stage biotech developing phage-based therapies against drug-resistant bacterial infections including MRSA. Comparable as a developer of novel non-traditional antimicrobials (peptides vs. phages) pursuing the same hospital/ID-physician customer base for resistant infections.

TypeEmerging player
Description

US clinical-stage biotech developing engineered phage and CRISPR-enhanced antimicrobials targeting priority pathogens. Comparable as a technology-driven antimicrobial developer (AI/synthetic biology vs. CRISPR engineering) advancing novel modalities for AMR.

TypeEmerging player
Description

Clinical-stage biotech developing defined bacterial consortia to address recurrent C. difficile and other infection-driven indications. Comparable as a developer of novel microbiome-derived or microbiome-adjacent therapeutics for infectious disease, sharing a science-first licensing-friendly posture.

TypeBroad incumbent
Description

Global pharma with a dedicated antibacterial R&D effort and historical leadership in novel antibiotic commercialization. Comparable as a likely licensing partner for Amprologix and a broader incumbent that shapes market access, pricing benchmarks, and licensing deal economics in the AMR space.

TypeBroad incumbent
Description

Global pharma with an active AMR portfolio (e.g., recent acquisition of Arixa Pharmaceuticals) and decades of antibiotic commercialization experience. Comparable as a likely large-pharma licensing counterparty and as a benchmark for the broader AMR competitive landscape Amprologix must navigate.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Amprologix

Novel antibiotics (antimicrobial drug discovery)amprologix.com

Amprologix firmographics

Firmographics
Name
Amprologix
Legal name
Amprologix Limited
Website
https://amprologix.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Amprologix industry classification

Industry
Product category
Novel antibiotics (antimicrobial drug discovery)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Novel antibiotics
  • Antimicrobial peptides
  • Antibiotic drug discovery
  • Antimicrobial resistance
  • Peptide therapeutics

Where Amprologix is headquartered

Location

Headquarters

HQ city
Plymouth
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Amprologix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Licensing deals with pharmaceutical companies: Amprologix plans to license its antibiotic candidates to pharmaceutical companies for commercialization. Licensing deals targeted for NI01 nasal decolonization (2026, $200M+ market) and bacterial pneumonia (2027, $5B+ market).
  2. Grant and public funding: Significant funding from Innovate UK Biomedical Catalyst awards (£1M for Tobraderm project) and SBRI funding (£1.2m for early R&D). These grants support pre-clinical development and late-preclinical testing.
  3. Series A and subsequent funding rounds: Company has raised £740,000 in pre-Series A funding (October 2025) with plans for additional funds for first human trials in 2026. Target £5M Series-A funding for 2025 skin infection clinical trials.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Amprologix product offering

Product offering

Core offering

Amprologix develops Epidermicin NI01, a potent bactericidal peptide antibiotic and lead compound with no known resistance liabilities, targeting MRSA nasal decolonization, bacterial pneumonia, and topical skin/wound infections. The company also operates a proprietary AI-driven antimicrobial discovery platform that uses machine learning to identify and optimize novel peptide antibiotic candidates derived from the epidermicin family and deep-sea microorganisms. Its development pipeline is supported by an exclusively licensed compound family originally discovered by Prof Mat Upton at Manchester University.

Product overview

Amprologix is pioneering a family of new antibiotics to combat antimicrobial resistance. The core offering centers on Epidermicin NI01, a potent bactericidal peptide antibiotic with no known resistance liabilities. The company's portfolio includes the NI01 Family of novel therapeutics and an AI-Driven Antimicrobial Discovery Platform that accelerates drug candidate identification. The Tobraderm Project advances NI01 through late-preclinical testing for skin and wound infections. Together, these products form a pipeline targeting nasal decolonization (MRSA), bacterial pneumonia, and topical skin infections.

Differentiator

Problem solved

Functional benefit

Products and services

  • Epidermicin NI01 Amprologix's lead antibiotic compound, a potent bactericidal peptide antibiotic with no known resistance liabilities. It is being developed for nasal decolonization of MRSA (targeted for a 2026 licensing deal in a US$200M+ market), treatment of bacterial pneumonia (targeted for a 2027 licensing deal in a US$5B+ market), and topical use against skin and wound infections including impetigo and chronic wounds.
  • NI01 Family (Epidermicin peptide family) A family of novel peptide therapeutics derived from minor modifications to the NI01 peptide sequence, offering a wide range of potent yet narrow-spectrum antibacterial activity against multiple bacterial pathogens. The family targets indications including MRSA, bacterial pneumonia, and surface skin infections, and represents an entirely new class of antibiotic drugs with no known resistance liabilities.

Quantifiable outcome

  • NI01 at 3% concentration matched efficacy of Bactroban (mupirocin) in reducing MRSA bacteria in wound infection model with no observed resistance development
  • +2 more outcomes

Companies that use Amprologix

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Amprologix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Amprologix partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, minor and moderate.

  • University of PlymouthcoreStrategic or Co-development PartnerAmprologix was launched in 2018 in collaboration with University of Plymouth. CSO Prof Mat Upton is a professor at the university. The partnership focuses on translational research and antimicrobial discovery.
  • Ingenza LTDcoreStrategic or Co-development PartnerWorld-leading biotechnology company partnered with Amprologix for manufacturing of antibiotic compounds.
  • STFC (Science & Technology Facilities Council)coreTechnology or IntegrationPartnership to utilize cutting-edge machine learning algorithms to improve antibiotic properties through Amprologix's AI-driven drug discovery.
  • RefLab ApS (Copenhagen, Denmark)minorStrategic or Co-development PartnerCollaboration using ex vivo human skin microdialysis model to test pseudo-allergic reactions for NI01 topical skin therapy, without using animal models.
  • InClincoreImplementation/ SI/ Consulting PartnerGlobal CRO supporting both pre-clinical and clinical development of epidermicin NI01.
  • National Physical Laboratory (UK)minorStrategic or Co-development PartnerCollaboration with Dr Max Ryadnov to publish data on the novel mode of action of epidermicin NI01, published in iScience.
  • Saudi Biotechnology AcceleratormoderateGTM or Marketing PartnerAmprologix participated in the 2025 Accelerator Programme, attending the Final Forum in Riyadh. Part of Saudi Arabia's Vision 2030 strategy to become a regional biotechnology hub.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Amprologix competitors and assessment

Company assessment

Direct peers

  • Paratek Pharmaceuticals: US-based commercial-stage biopharma that developed and markets Nuzyra (omadacycline), a novel antibiotic approved for community-acquired pneumonia and skin infections. Directly comparable to Amprologix as a developer of branded, novel-mechanism antibiotics targeting similar indications and the AMR problem.
  • Melinta Therapeutics: US specialty biopharma with a portfolio of branded antibiotics (e.g., Baxdela) for serious and drug-resistant infections. Comparable as a focused commercial-stage novel antibiotics developer serving the same prescriber base (hospitals treating resistant infections) that Amprologix ultimately targets via licensing.
  • Iterum Therapeutics: Clinical-stage biopharma developing oral and IV antibiotics (e.g., sulopenem) for multi-drug resistant infections including community-acquired pneumonia and complicated UTIs. Comparable as a late-clinical developer of branded antibiotics targeting priority pathogens on the WHO list that Amprologix addresses.
  • BioVersys: Switzerland-based clinical-stage AMR biotech developing small-molecule antibiotics (e.g., alpibectir/BVL-GSK098) to overcome resistance in priority pathogens. Comparable as a European AMR-focused biotech pursuing a licensing-oriented business model against similar bacterial targets.
  • Helperby Therapeutics: UK-based clinical-stage company developing antibiotic resistance breakers and novel combinations to revive existing antibiotics. Comparable as a UK-headquartered AMR biotech in the same geographic ecosystem with a similar licensing/partnership-oriented commercial strategy.

Emerging players

  • Adaptive Phage Therapeutics: US clinical-stage biotech developing phage-based therapies against drug-resistant bacterial infections including MRSA. Comparable as a developer of novel non-traditional antimicrobials (peptides vs. phages) pursuing the same hospital/ID-physician customer base for resistant infections.
  • Locus Biosciences: US clinical-stage biotech developing engineered phage and CRISPR-enhanced antimicrobials targeting priority pathogens. Comparable as a technology-driven antimicrobial developer (AI/synthetic biology vs. CRISPR engineering) advancing novel modalities for AMR.
  • Vedanta Biosciences: Clinical-stage biotech developing defined bacterial consortia to address recurrent C. difficile and other infection-driven indications. Comparable as a developer of novel microbiome-derived or microbiome-adjacent therapeutics for infectious disease, sharing a science-first licensing-friendly posture.

Broad incumbents

  • GSK (GlaxoSmithKline): Global pharma with a dedicated antibacterial R&D effort and historical leadership in novel antibiotic commercialization. Comparable as a likely licensing partner for Amprologix and a broader incumbent that shapes market access, pricing benchmarks, and licensing deal economics in the AMR space.
  • Pfizer: Global pharma with an active AMR portfolio (e.g., recent acquisition of Arixa Pharmaceuticals) and decades of antibiotic commercialization experience. Comparable as a likely large-pharma licensing counterparty and as a benchmark for the broader AMR competitive landscape Amprologix must navigate.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Amprologix social profiles

Digital presence

Amprologix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Amprologix leadership team

Management profile

Number of profiles

Profiles4 records

Amprologix funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Amprologix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amprologix

What does Amprologix do?

Amprologix develops Epidermicin NI01, a potent bactericidal peptide antibiotic and lead compound with no known resistance liabilities, targeting MRSA nasal decolonization, bacterial pneumonia, and topical skin/wound infections. The company also operates a proprietary AI-driven antimicrobial discovery platform that uses machine learning to identify and optimize novel peptide antibiotic candidates derived from the epidermicin family and deep-sea microorganisms. Its development pipeline is supported by an exclusively licensed compound family originally discovered by Prof Mat Upton at Manchester University.

Is Amprologix a public or private company?

Amprologix is a private company. It is classified as venture growth investor backed and is currently operating.

When was Amprologix founded?

Amprologix was founded in 2018. It employs 1 to 10 people.

Where is Amprologix based?

Amprologix is headquartered in Plymouth, United Kingdom, in the Europe region.

How does Amprologix make money?

Three revenue lines are on record. Licensing deals with pharmaceutical companies are the primary driver. The others are grant and public funding and series A and subsequent funding rounds.

Who are Amprologix's main competitors?

Direct peers on record are Paratek Pharmaceuticals, Melinta Therapeutics, Iterum Therapeutics, BioVersys and Helperby Therapeutics. Emerging players are Adaptive Phage Therapeutics, Locus Biosciences and Vedanta Biosciences. Broad incumbents are GSK (GlaxoSmithKline) and Pfizer.

Does Amprologix have an API?

No public API is recorded for Amprologix.

What industry is Amprologix in?

Amprologix's product category is Novel antibiotics (antimicrobial drug discovery). Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-MedicalNovel antibiotic compound shows promise against MRSA skin infectionsA study found epidermicin NI01, an antibiotic from University of Plymouth spinout Amprologix, is as effective as standard care for MRSA skin infections. The results justify further pre-clinical development, including gel-based therapies for superficial infections. The team plans to advance to human clinical trials.AmprologixAmprologix secures £740,000 investment to accelerate development of next-generation antibiotics targeting drug-resistant infectionsAmprologix has secured £740,000 in seed funding, including £300,000 matched funding for a £1 million Innovate UK-supported R&D project, to advance its novel antibiotic Epidermicin NI01 through preclinical safety studies toward Phase I clinical trials targeting drug-resistant wound infections including MRSA. The investment was led by Plutus Investment Group LLP, with additional participation from other institutional and angel investors, and includes Dr Rita Dobmeyer joining the Amprologix board as a venture partner. The funding round also brings global CRO InClin to support preclinical and clinical development, with the company leveraging AI-aided drug discovery to accelerate its antimicrobial pipeline.InvestegateAmprologix raises £740,000 in Pre-Series A roundAmprologix, a portfolio company of Frontier IP and spinout from the University of Plymouth, has raised £740,000 in a pre-Series A funding round to advance its lead antibiotic candidate epidermicin NI01 through pre-clinical development toward Phase I human trials planned for 2026. The funding includes £300,000 in matched funding for the £1 million TOBRADERM R&D project supported by Innovate UK's Biomedical Catalyst programme, with investors including angel network Plutus Investment Group LLP and individual investors. The company is also preparing for a Series A round targeting £5 million to support first human clinical trials and portfolio expansion.News-MedicalNew spinout company to tackle drug-resistant infections with novel antibioticsA University of Plymouth spinout company, Amprologix, was launched to develop and commercialize new antibiotics, including epidermicin, to combat drug-resistant infections. A UK government review estimates drug-resistant infections will cause 10 million deaths annually by 2050, and the company has secured a partnership with Ingenza.